![Eva Ehrnrooth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Eva Ehrnrooth worked as a Medical Director in Oncology at Novo Nordisk A from 2006 to 2008, and at Genmab A from 2008 to 2010.
She is currently the Chief Medical Officer at IO Biotech, Inc. since 2017.
Dr. Ehrnrooth holds a doctorate degree from the University of Aarhus.
Anciens postes connus de Eva Ehrnrooth
| Sociétés | Poste | Fin |
|---|---|---|
| IO BIOTECH, INC. | Directeur Technique/Scientifique/R&D | 18/07/2023 |
| GENMAB A/S | Directeur Technique/Scientifique/R&D | 01/02/2010 |
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/05/2008 |
Formation de Eva Ehrnrooth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
30
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Genmab A/S
 Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
University of Aarhus
 University of Aarhus Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
